Presentation is loading. Please wait.

Presentation is loading. Please wait.

Validation of the Global Allergy and Asthma European Network (GA2LEN) chamber for trials in allergy: Innovation of a mobile allergen exposure chamber 

Published byBjørn Nielsen Modified over 5 years ago

Similar presentations

Presentation on theme: "Validation of the Global Allergy and Asthma European Network (GA2LEN) chamber for trials in allergy: Innovation of a mobile allergen exposure chamber "— Presentation transcript:

1 Validation of the Global Allergy and Asthma European Network (GA2LEN) chamber for trials in allergy: Innovation of a mobile allergen exposure chamber  Torsten Zuberbier, MD, Mark B. Abelson, MD, Cezmi A. Akdis, MD, Claus Bachert, MD, PhD, Uwe Berger, MBA, Carsten Bindslev- Jensen, MD, Georg Boelke, MD, Jean Bousquet, MD, Giorgio Walter Canonica, MD, Thomas B. Casale, MD, Marek Jutel, MD, Marek L. Kowalski, MD, Enzo Madonini, MD, Nikolaos G. Papadopoulos, MD, Oliver Pfaar, MD, Torsten Sehlinger, Karl-Christian Bergmann, MD  Journal of Allergy and Clinical Immunology  Volume 139, Issue 4, Pages (April 2017) DOI: /j.jaci Copyright © 2016 The Authors Terms and Conditions

2 Fig 1 The GA2LEN mobile exposure chamber.
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2016 The Authors Terms and Conditions

3 Fig 2 The GA2LEN mobile exposure chamber: interior layout. Numbers refer to seats for patients. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2016 The Authors Terms and Conditions

4 Fig 3 Comparison of response to 4000 and 8000 grass pollen grains/m3 exposure in allergic subjects (n = 16 patients). Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2016 The Authors Terms and Conditions

5 Fig 4 Reproducibility of EEC challenges in subsequent exposures. Eighteen allergic subjects were exposed 2 times to 4000 grass pollen grains/m3 for 90 minutes at intervals of 1 to 5 weeks between visits. A, VAS scores. B, PNIFs. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2016 The Authors Terms and Conditions

6 Fig 5 Comparison of response to grass pollen and placebo exposure in allergic subjects (grass pollen, n = 55; placebo, n = 30). Exposure was 4000 grass pollen grains/m3 (P < .0001). Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2016 The Authors Terms and Conditions

7 Fig 6 Comparison of response to grass pollen exposure in allergic subjects and nonallergic control subjects (n = 36 allergic subjects and 5 nonallergic control subjects). Exposure was 4000 grass pollen grains/m3. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2016 The Authors Terms and Conditions

8 Fig 7 No evidence of priming effect in 5 exposures in consecutive days (n = 6 patients). Exposure was 4000 grass pollen grains/m3. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2016 The Authors Terms and Conditions

9 Fig 8 No symptom increase after prolonged exposure (n = 17 patients). Exposure was 4000 grass pollen grains/m3. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2016 The Authors Terms and Conditions

Download ppt "Validation of the Global Allergy and Asthma European Network (GA2LEN) chamber for trials in allergy: Innovation of a mobile allergen exposure chamber "

Similar presentations

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.
Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy  Monica B. Arvidsson, MD, Olle.

Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy  Monica B. Arvidsson, MD, Olle.
Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo  Eli O. Meltzer, MD, Claus Bachert,

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo  Eli O. Meltzer, MD, Claus Bachert,
High-titer IgE antibody specific for pollen allergens in northern California is associated with both wheezing and total serum IgE  Elizabeth A. Erwin,

High-titer IgE antibody specific for pollen allergens in northern California is associated with both wheezing and total serum IgE  Elizabeth A. Erwin,
Lolium perenne peptides for treatment of grass pollen allergy: A randomized, double- blind, placebo-controlled clinical trial  Mohamed H. Shamji, PhD,

Lolium perenne peptides for treatment of grass pollen allergy: A randomized, double- blind, placebo-controlled clinical trial  Mohamed H. Shamji, PhD,
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Giant ragweed specific immunotherapy is not effective in a proportion of patients sensitized to short ragweed: Analysis of the allergenic differences.

Giant ragweed specific immunotherapy is not effective in a proportion of patients sensitized to short ragweed: Analysis of the allergenic differences.
Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,

Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,
Jan Lötvall, MD, Cezmi A. Akdis, MD, Leonard B

Jan Lötvall, MD, Cezmi A. Akdis, MD, Leonard B
Fluticasone furoate nasal spray reduces the nasal-ocular reflex: A mechanism for the efficacy of topical steroids in controlling allergic eye symptoms 

Fluticasone furoate nasal spray reduces the nasal-ocular reflex: A mechanism for the efficacy of topical steroids in controlling allergic eye symptoms 
The Editors' Choice Journal of Allergy and Clinical Immunology

The Editors' Choice Journal of Allergy and Clinical Immunology
Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis  Paul H. Ratner,

Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis  Paul H. Ratner,
Is 9 more than 2 also in allergic airway inflammation?

Is 9 more than 2 also in allergic airway inflammation?
Preventive effect of nasal filters on allergic rhinitis: A randomized, double-blind, placebo- controlled crossover park study  Peter Kenney, BSc, Ole Hilberg,

Preventive effect of nasal filters on allergic rhinitis: A randomized, double-blind, placebo- controlled crossover park study  Peter Kenney, BSc, Ole Hilberg,
International consensus on allergy immunotherapy

International consensus on allergy immunotherapy
Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel.

Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel.
Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis  George Philip, MD, Janet van Adelsberg, MD, Thomas Loeys, PhD, Nancy.

Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis  George Philip, MD, Janet van Adelsberg, MD, Thomas Loeys, PhD, Nancy.
The National Biome Initiative: An allergy perspective

The National Biome Initiative: An allergy perspective
Morten J. Christensen, MD, Per Stahl Skov, MD, DMSci, Lars K

Morten J. Christensen, MD, Per Stahl Skov, MD, DMSci, Lars K
Treatment of chronic autoimmune urticaria with omalizumab

Treatment of chronic autoimmune urticaria with omalizumab

Similar presentations

Ads by Google